PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Opicapone - Parkinson's disease

PAD Profile : Opicapone - Parkinson's disease

Keywords :
Parkinsons disease, PD, COMT inhibitors, catechol-o-methyltransferase inhibitors
Brand Names Include :
Ongentys

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Capsules
Important Information :
2nd line COMT inhibitor. Entacapone is the locally agreed 1st-line choice
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

COMT inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

  • Entacapone is the locally agreed 1st-choice COMT inhibitor (BLUE no information sheet)
  • Opicapone is the locally agreed 2nd-choice COMT inhibitor (BLUE no information sheet)
  • Tolcapone is the locally agreed 3rd-choice COMT inhiitor (AMBER shared care)


Initiation is to be carried out in in secondary care and prescribed by a specialist for a minimum of 2 months, doses stabilised and response to treatment reviewed prior to any transfer request to primary care.

Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More